The effects of treprostinil, a synthetic analogue of prostacyclin with potent vasodilator properties, on exercise capacity and NT-proBNP are currently under investigation in a trial (n ~ 300) of HFpEF and PHT. Here, NPPB is linked to pulmonary hypertension, primary, 1.